Torrent Pharmaceuticals Ltd. benchmarking: Performance to industry peers

Financial

	Torrent Pharma	Dr. Reddy's Lab	Cipla
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	172.0 .	371.0 .	282.0 .
Number of ANDA's Approved By USFDA	132.0 .	300.0 .	228.0 .
Domestic Sales Growth - YoY	11.6 %	11.3 %	7.7 %
R&D as a % of Total Sales	5.0 %	7.0 %	7.0 %
Financials
5 yr Average ROE	20.79 %	15.68 %	13.9 %
5yr average Equity Multiplier	2.16	1.41	1.25
5yr Average Asset Turnover Ratio	0.69	0.74	0.78
5yr Avg Net Profit Margin	13.95 %	15.18 %	14.31 %
Price to Book	17.55	2.8	3.17
P/E	65.25	25.26	22.96
5yr Avg Cash Conversion Cycle	-186.79 Days	74.48 Days	-4.31 Days
Inventory Days	54.98 Days	76.14 Days	57.83 Days
Days Receivable	40.18 Days	95.44 Days	50.64 Days
Days Payable	298.32 Days	102.6 Days	105.99 Days
5yr Average Interest Coverage Ratio	7.38	35.66	53.73
5yr Avg ROCE	25.78 %	21.82 %	19.36 %
5yr Avg Operating Profit Margin	30.49 %	23.61 %	23.02 %
5 yr average Debt to Equity	0.66	0.12	0.03
5yr CAGR Net Profit	8.83 %	23.71 %	17.0 %
5yr Average Return on Assets	9.73 %	11.24 %	11.19 %
Shareholdings
Promoter Holding	68.31 %	26.63 %	29.21 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-2.94 %	-0.07 %	-4.34 %
Change in Mutual Fund Holding (3 Yrs)	-1.92 %	3.32 %	3.66 %

Business

	Torrent Pharma	Dr. Reddy's Lab	Cipla
Product Wise Break-Up	Product Wise Break-Up Domestic Formulations 42.15 US Formulations 20.71 Germany 13.15 Brazil 8.98 Contract Manufacturing 6.15 Proprietary Products 0 Global Generics 0 0 New ventures 0 Pharmaceuticals 0 Others 8.86	Product Wise Break-Up New ventures 0 Pharmaceuticals 0 US Formulations 0 Contract Manufacturing 0 Domestic Formulations 0 Formulations 89.21 Proprietary 0.17 Pharmaceutical 10.62 Brazil 0 Germany 0	Product Wise Break-Up New ventures 5.35 Pharmaceutical 94.65 US Formulations 0 Contract Manufacturing 0 Domestic Formulations 0 Global Generics 0 Proprietary Products 0 0 Brazil 0 Germany 0
Location Wise Break-Up	Location Wise Break-Up India 54.44 Brazil 11.23 USA 9.72 Germany 9.2 Russia 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 15.41	Location Wise Break-Up Global API 0 Russia 7.99 Emerging Markets 0 SAGA 0 Rest of the World 0 USA 48.56 Europe 0 North America 0 India 17.36 Brazil 0 Germany 0 Others 26.09	Location Wise Break-Up Global API 2.0 Russia 0 Emerging Markets 0 SAGA 14.0 Rest of the World 0 USA 0 Europe 13.0 North America 21.0 India 49.0 Brazil 0 Germany 0 Others 1.0
Acute vs Chronic	Acute vs Chronic Chronic 76.0 Acute 24.0 Sub - chronic 0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 25.0 Gastro Intestinal 17.0 CNS 15.0 VMN 11.0 Anti - Diabetes 10.0 Pain Management 7.0 Gynecology 2.0 Anti-Infective 2.0 Rest 2.0 Respiratory 0 Anti-Infective 0 Central Nervous System 0 Pain Management 0 Cardiovascular 0 Oncology 0 Gastrointestinal 0 Others 9.0	Therapeutic Area Break-Up Gastro Intestinal 0 Rest 0 Respiratory 7.04 Oncology 27.53 Gastro Intestinal 9.52 CNS 0 Cardiac Science 0 Anti - Diabetes 0 Pain Management 9.77 VMN 0 Gynecology 0 Central Nervous System (CNS) 12.12 Anti-Infective 6.48 Cardiac Science 6.65 Others 20.89	-
Asset Break-Up	Asset Break-Up India 94.39 USA 0.46 United States 0 Switzerland 0 South Africa 0 Others 5.15	Asset Break-Up USA 2.37 Switzerland 8.45 South Africa 0 USA 0 India 80.24 Others 8.94	Asset Break-Up United States 0 Switzerland 0 South Africa 18.03 USA 28.99 India 49.7 Others 3.28

Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

Financial

Business

SIGN UP FOR FREE